Bioresorbable Scaffolds Market Research Report, by Material (absorbable magnesium stent (AMS), polymeric scaffold, poly carbonate scaffold and others), by Types (drug eluting coronary scaffolds, everolimus-eluting device, novolimus-eluting device, sirolimus-eluting device, paclitaxel-eluting device), by Applications (peripheral vascular intervention, regulation of blood flow and others) by End Users (hospitals, clinics and others) - Forecast till 2032

Bioresorbable Scaffolds Market Overview

Bioresorbable scaffolds Market Size was valued at USD 1.62 Billion in 2023. The Bioresorbable scaffolds industry is projected to grow from USD 1.71 Billion in 2024 to USD 3.02 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 19.45% during the forecast period (2024 - 2032). Bioresorbable scaffolds are medical devices used during numerous surgeries, as required when one suffers from coronary artery disease; bioresorbable scaffolds are recently introduced medical devices. Major driving factors for the growth of this market are increasing prevalence of cardiovascular disease, diabetes, obesity, poor diet and lack of exercise. According to WHO (2014), cardiovascular diseases accounted for a majority of deaths globally.

Moreover, number of obese population across the globe is rising continuously. In 2014, globally 39% of adults aged 18 years and above were overweight, whereas 13% were obese. Furthermore, rapid development in devices used for cardiovascular surgeries, rising demand for bioresorbable scaffolds, adoption of desk-bound lifestyle, and government’s support for research and development of better medical devices has fuelled the bioresorbable scaffolds market growth. However, availability of alternative therapies and high cost of the bioresorbable scaffolds may slower the growth of this market.

Bioresorbable Scaffolds Market Segment Insights

The bioresorbable scaffolds market is segmented on the basis of material, types, application and end users. On the basis of material, the market is classified into absorbable magnesium stent (AMS), polymeric scaffold, poly carbonate scaffold and others. On the basis of types, the market is segmented into drug eluting coronary scaffolds, everolimus-eluting device, novolimus-eluting device, sirolimus-eluting device, and paclitaxel-eluting device. On the basis of application, the market is segmented into peripheral vascular intervention, regulation of blood flow and others. On the basis of end users, the market is categorised into hospitals, clinics and others.

Bioresorbable Scaffolds Market Regional Analysis

The global bioresorbable scaffolds market is dominated by America, owing to the presence of huge population suffering from cardiovascular diseases, presence of number of leading companies and increasing geriatric population. Moreover, increasing obese and diabetic population, lack of exercise, increasing stress and desk-bound lifestyle have provided a push for the growth of the market. Europe has the second largest market, which is followed by Asia Pacific. Asia Pacific accounts for the fastest growing market, due to rapid development in technology and a huge number of patients suffering from different vascular diseases. The Middle East & Africa accounts the least share in global bioresorbable scaffolds market.

Bioresorbable Scaffolds Market Key Players

• Abbott (US)


• Medtronic (UK)


• Boston Scientific Corporation (US)


• Biotronik (Germany)


• Elixir Medical Corporation (US)


• REVA Medical, Inc (US)


• Amaranth Medical, Inc. (US)


• Kyoto Medical Planning Co. Ltd. (Japan)


• Xenogenics Corporation (US)


• B. Braun (Germany)


• Cardinal Health. (US)


• Lombard Medical, Inc (UK)


• Translumina (Germany)


• MicroPort Scientific Corporation (China)


• TERUMO CORPORATION (Japan).

Bioresorbable Scaffolds Market Intended Audience

• Medical devices manufacturing companies


• Research and development (R&D) companies


• Government and independent research laboratories


• Government and independent regulatory authorities


• Academic medical institutes and universities


• Pharmaceutical industries